Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation.

NCT00429299 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00429299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00429299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2006
Completion date
June 30, 2012
Enrollment
121 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast